These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 26402986)
1. Efficacy of long-term low-dose sulodexide in diabetic and non-diabetic nephropathies. Zilişteanu DS; Atasie T; Voiculescu M Rom J Intern Med; 2015; 53(2):161-9. PubMed ID: 26402986 [TBL] [Abstract][Full Text] [Related]
2. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Sulikowska B; Olejniczak H; Muszyńska M; Odrowaz-Sypniewska G; Gaddi A; Savini C; Cicero AF; Laghi L; Manitius J Am J Nephrol; 2006; 26(6):621-8. PubMed ID: 17191008 [TBL] [Abstract][Full Text] [Related]
3. Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria. Yongwatana K; Supasyndh O; Satirapoj B J Diabetes Res; 2020; 2020():2984680. PubMed ID: 32851094 [TBL] [Abstract][Full Text] [Related]
4. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system. Benck U; Haeckel S; Clorius JH; van der Woude FJ Clin J Am Soc Nephrol; 2007 Jan; 2(1):58-67. PubMed ID: 17699388 [TBL] [Abstract][Full Text] [Related]
5. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Lambers Heerspink HJ; Fowler MJ; Volgi J; Reutens AT; Klein I; Herskovits TA; Packham DK; Fraser IR; Schwartz SL; Abaterusso C; Lewis J; Diabet Med; 2007 Nov; 24(11):1290-5. PubMed ID: 17956455 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. Blouza S; Dakhli S; Abid H; Aissaoui M; Ardhaoui I; Ben Abdallah N; Ben Brahim S; Ben Ghorbel I; Ben Salem N; Beji S; Chamakhi S; Derbel A; Derouiche F; Djait F; Doghri T; Fourti Y; Gharbi F; Jellouli K; Jellazi N; Kamoun K; Khedher A; Letaief A; Limam R; Mekaouer A; Miledi R; Nagati K; Naouar M; Sellem S; Tarzi H; Turki S; Zidi B; Achour A; J Nephrol; 2010; 23(4):415-24. PubMed ID: 20175052 [TBL] [Abstract][Full Text] [Related]
7. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats. Cha JJ; Kang YS; Hyun YY; Han SY; Jee YH; Han KH; Han JY; Cha DR Life Sci; 2013 Jun; 92(23):1118-24. PubMed ID: 23643633 [TBL] [Abstract][Full Text] [Related]
8. Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: the Gonryo study. Nakayama M; Sato T; Miyazaki M; Matsushima M; Sato H; Taguma Y; Ito S Hypertens Res; 2011 Oct; 34(10):1106-10. PubMed ID: 21796127 [TBL] [Abstract][Full Text] [Related]
9. One year course of oral sulodexide in the management of diabetic nephropathy. Achour A; Kacem M; Dibej K; Skhiri H; Bouraoui S; El May M J Nephrol; 2005; 18(5):568-74. PubMed ID: 16299683 [TBL] [Abstract][Full Text] [Related]
10. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345 [TBL] [Abstract][Full Text] [Related]
11. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Li R; Xing J; Mu X; Wang H; Zhang L; Zhao Y; Zhang Y Drug Des Devel Ther; 2015; 9():6275-83. PubMed ID: 26664049 [TBL] [Abstract][Full Text] [Related]
12. [Sulodexid and nephrotic syndrome in patients with diabetic nephropathy]. Valociková I Vnitr Lek; 2011 May; 57(5):507-10. PubMed ID: 21695933 [TBL] [Abstract][Full Text] [Related]
13. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Ruggenenti P; Perna A; Mosconi L; Matalone M; Pisoni R; Gaspari F; Remuzzi G Kidney Int Suppl; 1997 Dec; 63():S54-7. PubMed ID: 9407422 [TBL] [Abstract][Full Text] [Related]
14. Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy. Bang K; Chin HJ; Chae DW; Joo KW; Kim YS; Kim S; Ju KD; Kim H; Ahn C; Oh KH Yonsei Med J; 2011 Jul; 52(4):588-94. PubMed ID: 21623600 [TBL] [Abstract][Full Text] [Related]
15. [A trial of the use of the low-molecular heparin sulodexide in the therapy of diabetic nephropathy]. Zalevskaia AG; Astamirova KhS; Karpova IA; Popova SG Ter Arkh; 1998; 70(3):71-4. PubMed ID: 9575594 [TBL] [Abstract][Full Text] [Related]
16. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. Evans M; Bain SC; Hogan S; Bilous RW; Nephrol Dial Transplant; 2012 Jun; 27(6):2255-63. PubMed ID: 22172728 [TBL] [Abstract][Full Text] [Related]
17. [The efficacy of Sulodexide--a low-molecular heparin--in the therapy of diabetic nephropathy]. Shestakova MV; Chugunova LA; Vorontsov AV; Dedov II Ter Arkh; 1997; 69(6):34-7. PubMed ID: 9297270 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy. Aggarwal HK; Jain D; Talapatra P; Yadav RK; Gupta T; Kathuria KL Ren Fail; 2010; 32(8):941-6. PubMed ID: 20722561 [TBL] [Abstract][Full Text] [Related]
19. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. Packham DK; Wolfe R; Reutens AT; Berl T; Heerspink HL; Rohde R; Ivory S; Lewis J; Raz I; Wiegmann TB; Chan JC; de Zeeuw D; Lewis EJ; Atkins RC; J Am Soc Nephrol; 2012 Jan; 23(1):123-30. PubMed ID: 22034636 [TBL] [Abstract][Full Text] [Related]
20. The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease. Tsuboi N; Kawamura T; Okonogi H; Ishii T; Hosoya T J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):113-7. PubMed ID: 21729991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]